Physician profile
Frederic Dewil
NPI 1790711810
$548.38
in general payments reported to CMS, 2019-2025
11 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $13.39 · 2021: $37.54 · 2022: $87.48 · 2023: $108 · 2024: $36.92 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $241.76 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $52.49 | 2019-2023 | Breztri |
| Insmed, INC. | $52.48 | 2025 | Arikayce |
| Verona Pharma, INC. | $51.07 | 2025 | Ohtuvayre |
| Philips North America LLC | $33.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.45 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $24.64 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $21.52 | 2024 | Lumryz |
| Gilead Sciences, INC. | $14.20 | 2021 | |
| Harmony Biosciences LLC | $13.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Dewil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.